Research feed
Recently added diabetes research, organized by intervention and outcome.
Sorted by when Dediabetes added each study.
A study found that supervised home-based elastic band exercises significantly improved health outcomes in pre-frail older adults with type 2 diabetes.
This study evaluated the effectiveness of eldecalcitol in preventing type 2 diabetes in adults with impaired glucose tolerance. It found no significant difference in diabetes incidence between eldecalcitol and placebo groups.
This study compared the effects of empagliflozin and pioglitazone on echocardiographic indices in patients with type 2 diabetes and nonalcoholic fatty liver disease, finding significant improvements in certain measures.
The study evaluated the effects of empagliflozin on glycemic control in adults with HNF1A-MODY, finding significant reductions in glucose levels and improvements in time in range.
This study evaluated the effects of empagliflozin on diastolic function in patients with type 2 diabetes and elevated end-diastolic pressure, finding significant improvements in various cardiovascular and metabolic parameters.
This study tested the SGLT2 inhibitor empagliflozin in 79 people with type 2 diabetes and early kidney disease over 24 weeks. While empagliflozin showed early improvements in albumin excretion at 4 and 12 weeks, the difference was not significant by 24 weeks. However, it did reduce certain hypoxia-related proteins in the blood that may contribute to kidney damage.
This study compared the effects of empagliflozin and glimepiride on endothelial function in individuals with type 2 diabetes, finding no significant differences in flow-mediated dilation but notable differences in body weight and fluid volume.
This study looked at whether attending more sessions of a diabetes prevention programme helped lower type 2 diabetes risk. People who went to all sessions had an 88% lower risk of developing diabetes compared to those receiving standard care. However, fewer than 1 in 3 people attended all sessions.
This study compared the Equil patch insulin pump and the Medtronic MMT-712 insulin pump in treating Type 2 diabetes, finding no significant differences in key outcomes.
The study evaluated the effects of ertugliflozin on cardiac function in individuals with type 2 diabetes and pre-heart failure, finding significant improvements in certain cardiac metrics.
Latest Evidence
Build your workspace to keep track of the latest diabetes research.
